Crescent Capital BDC opened lower at $10.22, compared with its previous close of $10.25. In the last trading session, the stock traded between $10.01 and $10.22. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Crescent Capital BDC is now worth
$ 49.58
Resulting in a loss of
$ 50.42 (50.42%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
28.57%
Hold
71.43%
Sell
0%
Markets Today
Today's Change
$-0.14 (-1.32%)
Day High
$10.22
Day Low
$10.01
Day Open
$10.22
Prev Close
$10.25
Volume
1,40,351
1W Return
4.83%
1M Return
10.58%
3M Return
-11.50%
6M Return
-22.90%
1Y Return
-28.97%
Fundamentals
Market Cap ($ Mn)
373
PE Ratio
-
PB Ratio
0.59
PEG Ratio
-
ROE
4.78%
ROCE
-
EPS (TTM)
$0.27
Investment Returns
1 Week
4.83%
1 Month
10.58%
3 Months
-11.50%
6 Months
-22.90%
9 Months
-29.56%
Financials
Quarterly
All values in $ Mn
41.1
Jun 25
31.5
Sep 25
32.8
Dec 25
6.9
Mar 26
20.2
Jun 26
33.3
Sep 26
Updates
11Nov
Wells Fargo lowers Crescent Capital BDC price target to $10
Wells Fargo lowered the price target for Crescent Capital BDC from $11 to $10. The brokerage maintained an Equal-Weight rating on the stock. Analyst Finian O'Shea made the revision to the valuation.
Yesterday
10Nov
Crescent Capital BDC Q3FY26 Results: NII up 3% QoQ, launches $150m JV
Net investment income rose to $0.37 per share in Q3 2026, covering the $0.34 base dividend. A new $150 million joint venture is planned to accelerate deleveraging and fund share buybacks. Total investment income increased QoQ to $36.9 million despite subdued LBO market activity. Watch list expanded to 16% of portfolio, while nonaccruals improved slightly to 4.7%. Sun Life committed an additional $25 million to purchase CCAP shares alongside the company's $50 million program.
2 days ago
11Aug
Crescent Capital BDC Q2 Adj. EPS $0.36 misses $0.37 estimate
Crescent Capital BDC missed Q2 analyst estimates with adjusted EPS of $0.36 versus $0.37 expected, and sales of $36.32 million versus $37.32 million. The results reflect a 21.7% YoY EPS decline and 15.5% YoY sales drop, driven by lower dividend income and reduced fee activity despite stable interest income.
3mo ago
16Jun
Keefe lowers Crescent Capital BDC target to $13
Keefe, Bruyette & Woods analyst Paul Johnson maintains an Outperform rating on Crescent Capital BDC but cuts the price target to $13 from $15.
